Treatment goals and quality of life (QOL) in a survey of patients with ER+/HER2-metastatic breast cancer (mBC)

被引：0
|
作者：
Sammons, Sarah L.
Meisel, Jane
Shanahan, Kelly
Pluard, Timothy
Kozlowski, Monica
Carroll, Dominic
Attias, Elizabeth
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P6-09-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-09-01
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Vaginal and sexual health in patients with ER+/HER2-metastatic breast cancer (mBC)
    Shanahan, Kelly
    Sammons, Sarah
    Meisel, Jane L.
    Pluard, Timothy J.
    Kozlowski, Monica
    Carroll, Dominic
    Attias, Elizabeth
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2023, 30 (12): : 1296 - 1296
  • [2] Minimization of treatment toxicity/side effects and their impact on quality of life (QoL) in patients (pts) with ER+/HER2metastatic breast cancer (mBC)
    Sammons, Sarah
    Meisel, Jane
    Shanahan, Kelly
    Pluard, Timothy
    Chino, Fumiko
    Trapani, Dario
    Carroll, Dominic
    Kozlowski, Monica
    Attias, Elizabeth
    Kuderer, Nicole
    CANCER RESEARCH, 2024, 84 (09)
  • [3] Targeted therapies for ER+/HER2-metastatic breast cancer
    Yamamoto-Ibusuki, Mutsuko
    Arnedos, Monica
    Andre, Fabrice
    BMC MEDICINE, 2015, 13
  • [4] Knowledge of tumor/blood genomic testing (NGS) and ESR1 mutations in a survey of patients with ER+/HER2-metastatic breast cancer (mBC)
    Meisel, Jane
    Sammons, Sarah L.
    Shanahan, Kelly
    Pluard, Timothy
    Kozlowski, Monica
    Carroll, Dominic
    Attias, Elizabeth
    CANCER RESEARCH, 2023, 83 (05)
  • [5] BUDGET IMPACT ANALYSIS OF EVEROLIMUS FOR ER+, HER2-METASTATIC BREAST CANCER PATIENTS IN THE UNITED STATES
    Xie, J.
    Diener, M.
    De, G.
    Wu, E. Q.
    Namjoshi, M.
    VALUE IN HEALTH, 2012, 15 (04) : A212 - A212
  • [6] Efficacy and safety of everolimus for heavily pretreated patients with ER+/HER2-metastatic breast cancer.
    Osako, Tomofumi
    Nishimura, Reiki
    Nishiyama, Yasuyuki
    Fujisue, Mamiko
    Yamada, Mitsuhiro
    Suko, Kyoko
    Morioka, Junko
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Prediction of early progression (EP) to CDKIs first line treatment in ER+/HER2-metastatic breast cancer (MBC) using machine learning.
    Manuel Jerez, Jose
    Ribelles, Nuria
    Rodriguez-Brazzarola, Pablo
    Diaz Redondo, Tamara
    Jimenez Rodriguez, Begona
    Sanchez-Munoz, Alfonso
    Marquez, Antonia
    Carabantes, Francisco
    Pajares, Bella
    Villar, Ester
    Bermejo-Perez, Maria-Jose
    Saez Lara, Enrique
    Emilia Dominguez-Recio, Maria
    Godoy, Ana
    Mesa, Hector
    Galvez Carvajal, Laura
    Franco, Leo
    Ruiz, Sofia
    Lopez, Irene
    Alba, Emilio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2+or HER2-metastatic breast cancer
    Hunter, Natasha
    Peterson, Lanell M.
    Mankoff, David A.
    Muzi, Mark
    Chen, Delphine
    Gwin, William R.
    Vinayak, Shaveta
    Davidson, Nancy E.
    Specht, Jennifer M.
    Linden, Hannah
    CANCER RESEARCH, 2023, 83 (05)
  • [9] Quality of life (QoL) improvements with capecitabine in patients with metastatic breast cancer (MBC)
    Segalla, J.
    Tosello, C.
    Ribeiro, R.
    Tessaro, S.
    Cabral, S.
    Perdicaris, M. R.
    Moura, G. L.
    Lago, S.
    Garicochea, B.
    Abdo, E.
    EJC SUPPLEMENTS, 2005, 3 (02): : 115 - 115
  • [10] Treatment patterns and clinical outcomes in ER+/HER2-metastatic breast cancer in German real world settings
    Mitra, D.
    Kurosky, S.
    Kaye, J.
    Harbeck, N.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S141 - S141
12345